8144 E. Cactus Rd, Ste 820, Scottsdale, AZ 85260

Low-Dose Naltrexone (LDN)

An immune-modulating therapy that may help your body fight cancer while improving quality of life.

What is Low-Dose Naltrexone?

Low-dose naltrexone (LDN) is an off-label use of the medication naltrexone at very low doses (typically 1.5-4.5mg, compared to the standard 50mg dose used for addiction). At these low doses, naltrexone acts as an immune modulator rather than an opioid blocker, triggering beneficial changes in immune function that may help the body fight cancer.

LDN has gained significant attention in integrative oncology due to its potential to enhance immune function, reduce inflammation, and improve quality of life with minimal side effects and low cost. While research is still emerging, clinical experience and preliminary studies show promise for cancer patients.

How LDN Works

LDN's mechanism of action is unique and involves a "rebound effect" on your body's natural opioid system:

Endorphin Boost

LDN temporarily blocks opioid receptors, triggering your body to produce more endorphins and enkephalins (natural opioids). When the blockade wears off, these elevated levels enhance immune function.

Immune Enhancement

Elevated endorphins stimulate natural killer (NK) cells and T-cells - key immune cells that recognize and destroy cancer cells. This enhanced immune surveillance may help control cancer growth.

Anti-Inflammatory

LDN has been shown to reduce inflammatory markers and modulate the inflammatory response, creating a less favorable environment for cancer progression.

OGF Pathway

LDN may work through the Opioid Growth Factor (OGF) pathway, which has been shown in laboratory studies to inhibit cell proliferation in certain cancer types.

Research on LDN and Cancer

While large-scale clinical trials are still needed, existing research shows promise:

  • Pancreatic Cancer: Penn State studies showed LDN combined with standard chemotherapy significantly improved survival in pancreatic cancer patients
  • Cell Line Studies: Laboratory research has demonstrated LDN's ability to inhibit growth in various cancer cell lines including ovarian, pancreatic, and colon cancer
  • Quality of Life: Multiple clinical studies show LDN improves fatigue, pain, and overall well-being in cancer patients
  • Immune Function: Studies demonstrate measurable increases in NK cell activity and other immune parameters

Dr. Ian Zagon at Penn State University has been researching LDN's anti-cancer mechanisms for decades, providing a scientific foundation for its clinical use.

Potential Benefits for Cancer Patients

  • Enhanced Immune Function: Increased natural killer cell activity and immune surveillance
  • Improved Quality of Life: Better energy, mood, and overall well-being
  • Pain Reduction: May help reduce cancer-related pain through endorphin elevation
  • Better Sleep: Many patients report improved sleep quality
  • Minimal Side Effects: Generally very well tolerated with few adverse effects
  • Low Cost: Inexpensive therapy accessible to most patients
  • Anti-Inflammatory Effects: Reduction in inflammatory markers
  • Easy Administration: Simple once-daily oral capsule

What to Expect

Getting Started

LDN is available by prescription and must be compounded by a specialty pharmacy at the low doses used therapeutically. After evaluating your medical history and current medications, Dr. Stallone will determine if LDN is appropriate for you and prescribe a customized dose.

Dosing Protocol
  • Starting Dose: Typically begin at 1.5mg and gradually increase
  • Target Dose: Most patients reach 3-4.5mg over several weeks
  • Timing: Usually taken at bedtime to align with natural endorphin production cycles
  • Gradual Increase: Starting low minimizes any initial side effects
What to Expect Initially

Some patients experience vivid dreams or mild sleep disturbances during the first 1-2 weeks as the body adjusts. These effects typically resolve as you continue treatment. Starting with a lower dose and gradually increasing helps minimize these initial effects.

Timeline for Benefits

Most patients begin noticing improvements in energy and well-being within 2-4 weeks. Immune-enhancing effects continue to develop over several months of consistent use. LDN is typically continued long-term as part of an integrative cancer care protocol.

Important Considerations

Opioid Medication Interaction

LDN blocks opioid receptors and cannot be used by patients currently taking opioid pain medications (such as morphine, oxycodone, hydrocodone, etc.). If you require opioid pain medication, you would need to transition to non-opioid alternatives before starting LDN, which must be done carefully under medical supervision.

LDN is generally well-tolerated, but it's not appropriate for everyone. We'll review your complete medication list and medical history to ensure LDN is safe and suitable for your situation.

Frequently Asked Questions

Yes, LDN can generally be used alongside chemotherapy. Some research suggests it may even enhance chemotherapy effectiveness while reducing side effects. However, timing and specific drug interactions should be reviewed individually.

LDN is remarkably well-tolerated. The most common side effects are vivid dreams and mild sleep disturbances during the first 1-2 weeks, which typically resolve. Some patients experience mild headache or nausea initially. Serious side effects are rare.

LDN is typically used long-term as an ongoing immune support therapy. Many cancer patients continue taking it indefinitely as part of their integrative protocol, given its excellent safety profile and low cost.

Naltrexone is a generic medication, meaning there's little financial incentive for pharmaceutical companies to fund large clinical trials. While research continues at academic institutions, widespread adoption awaits larger studies. Many integrative oncologists include LDN based on existing evidence and clinical experience.

Ready to Boost Your Immune System with LDN?

Schedule a consultation to learn how low-dose naltrexone can support your body's fight against cancer.